PMID: 9421099Jan 8, 1998Paper

Itraconazole decreases renal clearance of digoxin

Therapeutic Drug Monitoring
K M JalavaP J Neuvonen

Abstract

Itraconazole strongly interacts with some drugs metabolized by cytochrome P450 3A4, for example, felodipine and lovastatin, by inhibiting their metabolism. A concomitant use of itraconazole increases the serum concentrations of digoxin, although digoxin is excreted mainly unchanged in urine. To reveal the mechanism of the itraconazole-digoxin interaction, the effect of itraconazole on the serum concentrations and urinary excretion of digoxin was studied. Ten healthy volunteers in a double-blind, randomized, two-phase crossover study received either 200 mg itraconazole or placebo orally once a day for 5 days. On day 3, each volunteer ingested a single 0.5-mg oral dose of digoxin. The serum concentrations of digoxin and its excretion into urine as well as plasma concentrations of itraconazole were determined up to 72 hours after dosing. The mean area under the serum digoxin concentration-time curve, AUC(0-72), was approximately 50% higher (P < 0.001) during the itraconazole phase than during the placebo phase. In addition, the renal clearance of digoxin decreased about 20% (P < 0.01) by itraconazole. The increases in digoxin Cmax and T(1/2) by itraconazole were not statistically significant. The decreased renal clearance of digox...Continue Reading

References

May 1, 1979·Clinical Pharmacology and Therapeutics·M H GaultM Tweeddale
Apr 1, 1976·Clinical Pharmacology and Therapeutics·J H Caldwell, C T Cline
Mar 15, 1992·Annals of Internal Medicine·J Rex
Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A Kauffman, F A Bagnasco
Nov 30, 1992·Biochemical and Biophysical Research Communications·I A de Lannoy, M Silverman
Oct 1, 1991·Annals of Internal Medicine·A F CohenA van Vliet
Oct 1, 1982·Clinical Physiology·K Schenck-GustafssonR Dahlqvist
Oct 1, 1981·The New England Journal of Medicine·J LindenbaumJ R Saha
Feb 1, 1981·Clinical Pharmacology and Therapeutics·H GaultJ Barrowman
Feb 1, 1995·Therapeutic Drug Monitoring·H M DoddsS M Pond
May 1, 1994·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Jan 1, 1993·European Journal of Clinical Pharmacology·S Pohjola-SintonenP Neuvonen
Dec 6, 1993·The Medical Journal of Australia·C P Alderman, H P Jersmann
Mar 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M K SachsP J Green
Jul 1, 1996·Clinical Pharmacology and Therapeutics·P J Neuvonen, K M Jalava
Oct 1, 1996·Journal of Clinical Pharmacology·A BerndtM Weiss
Nov 1, 1996·Pharmacology & Toxicology·J PartanenP J Neuvonen
Apr 1, 1997·Clinical Pharmacology and Therapeutics·K M JalavaP J Neuvonen

❮ Previous
Next ❯

Citations

Jun 8, 2006·European Journal of Clinical Pharmacology·Mikko NiemiJanne T Backman
Jan 16, 2010·European Journal of Clinical Pharmacology·Teijo I SaariKlaus T Olkkola
May 25, 2010·European Journal of Clinical Pharmacology·Tuija TapaninenMikko Niemi
Mar 16, 2012·European Journal of Clinical Pharmacology·Tsuneaki YoshizatoKyoichi Ohashi
May 14, 2005·Critical Reviews in Oncology/hematology·Peter BlowerMatti Aapro
Jul 30, 1999·Journal of the American Academy of Dermatology·A K GuptaN H Shear
Feb 24, 2001·Journal of Clinical Psychopharmacology·L L von Moltke, D J Greenblatt
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Er-jia WangWilliam W Johnson
Jul 20, 1999·The Journal of Clinical Investigation·B GreinerH K Kroemer
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Sep 29, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David G Bailey, George K Dresser
Aug 5, 2011·Drugs & Aging·Vera H M Deneer, Norbert M van Hemel
Jul 27, 2011·Pharmacogenomics·Fabian Müller, Martin F Fromm
Dec 7, 2010·Journal of the American Medical Informatics Association : JAMIA·Kim R SavernoDaniel C Malone
Mar 1, 2012·Expert Opinion on Drug Metabolism & Toxicology·Eve-Irene Lepist, Adrian S Ray
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Kasra Shakeri-Nejad, Ralf Stahlmann
May 7, 2013·Expert Opinion on Drug Metabolism & Toxicology·Jodi Lestner, William W Hope
Jul 25, 2006·Expert Opinion on Drug Metabolism & Toxicology·Meng LiJoanne Wang
Oct 13, 2005·Expert Opinion on Pharmacotherapy·Paul O Gubbins, Jarrett R Amsden
Sep 25, 2001·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A Ayrton, P Morgan
Aug 1, 2008·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·L ZhangS-M Huang
Nov 4, 2004·British Journal of Clinical Pharmacology·T OsanaiS Kaneko
Aug 3, 2004·Journal of Clinical Pharmacology·Chetan S KaryekarThomas C Dowling
Apr 12, 2003·Pharmacotherapy·Chetan S KaryekarThomas C Dowling
Nov 18, 2003·British Journal of Clinical Pharmacology·Lynn PurkinsDon Nichols
May 1, 2015·The Journal of Membrane Biology·Zsolt FeketePeter Krajcsi
May 4, 2006·British Journal of Clinical Pharmacology·Mikiko ShimizuTomonori Tateishi
Oct 20, 2006·Journal of Clinical Pharmacology·Brian KirbyJashvant D Unadkat
Dec 21, 2005·Basic & Clinical Pharmacology & Toxicology·Jari J LiljaPertti J Neuvonen
Jun 27, 2006·British Journal of Clinical Pharmacology·Mikiko ShimizuTomonori Tateishi
Feb 22, 2012·Basic & Clinical Pharmacology & Toxicology·Pertti J Neuvonen
Dec 17, 2009·Mycoses·Paul O Gubbins, Seth Heldenbrand

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.